112 completed, 14 terminated, 11 unknown, 9 recruiting. 44 Phase 2, 37 Phase 1, 31 Phase 3, 29 Not applicable, 15 Phase 4.
Follow Inhalation: new trials by email Literature Review of Inhalation trials Research Report on Inhalation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours), Ceftriaxone for Injection, Amoxicillin - Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection | Phase 2 | Not yet recruiting | The University of Queensland | 300 | 2027-04-01 | 2026-03-20 |
| Symptomatic Hyperventilation in Individuals Living With Stroke Respiratory Function, Respiratory Muscle Strength, and Functional Capacity Assessments - Stroke, Hyperventilation Syndrome | Not yet recruiting | Istinye University | 92 | 2026-09-25 | 2026-09-25 | |
| Early Rehabilitation in Patients Following Major Cardiac Surgery: Changes in Functional Capacity and Energy Efficiency in Walking and ADLs. Use of COSMED K5, a portable metabolic system that allows real-time measurement of respiratory gas exchange, ventilation, and energy expenditure during physical activities. - Cardiac Surgery, Median Sternotomy | Not applicable | Active not recruiting | Istituti Clinici Scientifici Maugeri SpA | 60 | 2026-09-01 | 2026-10-05 |
| Pelvic Floor Dysfunction in Pulmonary Systemic Sclerosis Pelvic Floor Health Knowledge Assessment, Pelvic Floor Dysfunction Assessment, Core Endurance Assessment - Interstitial Lung Disease With Systemic Sclerosis | Completed | Biruni University | 37 | 2026-08-01 | 2026-10-14 | |
| A Phase 1a/1b Study to Investigate the Safety, Tolerability, Microbiological Response, and Pharmacokinetics of Inhaled Rev-56 in Adult Healthy Volunteers and Adult Non-cystic Fibrosis Bronchiectasis (NCFB) Patients With Chronic P. Aeruginosa Rev-56 for Inhalation, Placebo: Normal saline - Healthy Participants, Non-cystic Fibrosis Bronchiectasis | Phase 1 | Active not recruiting | Revagenix, Inc. | 64 | 2026-07-13 | 2026-10-14 |
| A Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS-9821 Powder for Inhalation Administered as a Single Dose in Healthy Participants and Multiple Doses in Patients With COPD HRS-9821 Powder for Inhalation, Placebo - COPD | Phase 1 | Recruiting | Guangdong Hengrui Pharmaceutical Co., Ltd | 48 | 2026-07-09 | 2026-07-20 |
| Clinical Trial With Aprotinin in the Acute Respiratory Distress Syndrome Treatment Aprotinin (inhaled), Placebo (Sodium Chloride) - Acute Respiratory Distress Syndrome (ARDS) | Phase 3 | Recruiting | Fundacion del Hospital Nacional de Paraplejicos para la Investigacion y la Integracion | 156 | 2026-06-18 | 2026-07-15 |
| A Single Dose, Dose Escalation Clinical Trial on the Safety, Tolerability and Efficacy of Lyophilized Powder for Inhalation of Recombinant Human Keratinocyte Growth Factor-2 (Rh-KGF-2) in The Treatment of Patients With Acute Respiratory Distress Syndrome Recombinant Human Keratinocyte Growth Factor-2 for Inhalation (Lyophilized Powder) - ARDS (Moderate or Severe), ARDS (Acute Respiratory Distress Syndrome) | Early Phase 1 | Recruiting | Shanghai Zhongshan Hospital | 24 | 2026-05-14 | 2026-06-11 |
| Effect of Pursed-Lip Breathing With Different I:E Ratios on Respiratory Outcomes in COPD Patients Participants perform PLB with inspiratory-expiratory ratio 1:3 (2 seconds inspiration, 6 seconds expiration), Participants perform PLB with inspiratory-expiratory ratio 1:4 (2 seconds inspiration, 8 seconds expiration), Participants perform PLB with inspiratory-expiratory ratio 1:5 (2 seconds inspiration, 10 seconds expiration) - Chronic Obstructive Pulmonary Disease (COPD) | Not applicable | Not yet recruiting | Scholastica Fina Aryu Puspasari | 122 | 2026-05-04 | 2026-05-07 |
| Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease TQC3721 Suspension for Inhalation - Chronic Obstructive Pulmonary Disease | Phase 3 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 800 | 2026-04-14 | 2026-09-28 |
| N2O for Acute Suicidality and Depression in the ED Nitrous oxide gas for inhalation, Placebo - Suicidal Ideation, Major Depressive Disorder | Phase 2 | Withdrawn | University of Chicago | 2026-02-27 | 2026-03-04 | |
| Modified Shenling Baizhu Powder for Allergic Asthma With Spleen Deficiency and Dampness Accumulation Syndrome Modified Shenling Baizhu Powder, Placebo, Budesonide and Formoterol Fumarate Powder for Inhalation - Allergic Asthma | Not applicable | Not yet recruiting | Henan University of Traditional Chinese Medicine | 400 | 2026-01-15 | 2026-01-20 |
| A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TQC3302 Inhalation Spray in Healthy Adult Subjects TQC3302 inhalation spray, TQC3302 inhalation spray+Tiotropium bromide and olodaterol hydrochloride inhalation spray +Budesonide Powder for Inhalation, Tiotropium bromide and olodaterol hydrochloride inhalation spray +Budesonide Powder for Inhalation+ TQC3302 inhalation spray - Chronic Obstructive Pulmonary Disease | Phase 1 | Terminated | Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd. | 33 | 2025-11-25 | 2026-08-27 |
| Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease TQC3721 Suspension for inhalation, Placebo of TQC3721 Suspension for Inhalation - Chronic Obstructive Pulmonary Disease | Phase 3 | Not yet recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 666 | 2025-09-01 | 2025-09-10 |
| Inhaled Colistin to Prevent Ventilator-Associated Pneumonia in Patients With Acute Brain Injury Inhaled colistin, Inhaled 0.9% sodium chloride - Ventilator-Associated Pneumonia (VAP), Inha'le'd | Not applicable | Recruiting | Southeast University, China | 444 | 2025-04-27 | 2026-09-15 |
| A Clinical Trial of TQC3927 Powder for Inhalation in Chronic Obstructive Pulmonary Disease TQC3927 powder for inhalation, TQC3927 powder for inhalation placebo - Chronic Obstructive Pulmonary Disease | Phase 1 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 48 | 2025-02-11 | 2025-08-15 |
| Strengthening Inspiratory and Oropharyngeal Muscles in Moderate Obstructive Sleep Apnea Hypopnea Syndrome Inspiratory and Oropharyngeal Muscle Strengthening - Obstructive Sleep Apnea | Not applicable | Recruiting | Centre Hospitalier Universitaire de Saint Etienne | 38 | 2024-12-30 | 2026-09-25 |
| Age-related Changes in Retinal Oxygen Extraction in Healthy Subjects Oxygen 100% Gas for Inhalation - Healthy Participants, Retinal Oxygen Extraction | Not applicable | Recruiting | Medical University of Vienna | 50 | 2024-09-30 | 2025-11-21 |
| A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease 3mg TQC3721 Suspension for Inhalation, 6mg TQC3721 Suspension for Inhalation, Placebo TQC3721 suspension for inhalation - Pulmonary Disease, Chronic Obstructive | Phase 2 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 240 | 2024-09-14 | 2025-04-11 |
| A Study of TQC3927 Powder for Inhalation in Healthy Adult Subjects TQC3927 powder for inhalation, TQC3927 powder for inhalation placebo - Chronic Obstructive Pulmonary Disease | Phase 1 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 60 | 2024-05-22 | 2024-10-29 |
Showing 20 of 163. Sign in to see all of them.
Pulmonary Disease, Chronic Obstructive (29) · Cystic Fibrosis (25) · Asthma (9) · COVID-19 (9) · Pseudomonas Infections (8) · Respiratory Aspiration (7) · Respiratory Tract Infections (7) · Bronchiolitis (4) · Depression (4) · Respiratory Distress Syndrome (4) · Bronchiectasis (3) · Depressive Disorder, Major (3) · Lung Diseases (3) · Mycobacterium Infections, Nontuberculous (3) · Neoplasms (3)
Boehringer Ingelheim (10) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (8) · Insmed Incorporated (8) · Amgen (4) · Mallinckrodt (4) · Peking University First Hospital (4) · Aradigm Corporation (3) · AstraZeneca (3) · Henan University of Traditional Chinese Medicine (3) · Kamada, Ltd. (3) · University of Chicago (3) · Windtree Therapeutics (3) · Amphastar Pharmaceuticals, Inc. (2) · Boston Children's Hospital (2) · Canadian Network for Observational Drug Effect Studies, CNODES (2)
United States (58) · China (33) · United Kingdom (18) · Canada (17) · Germany (14) · Spain (12) · Netherlands (10) · Poland (10) · France (9) · Belgium (8) · Hungary (8) · Australia (7) · Austria (6) · Ireland (6) · Israel (6)
Gina Eagle, MD (6) · Dong-Xin Wang, MD, PhD (3) · Peter Nagele, MD, MSc (3) · George Retsch-Bogart, MD (2) · Pierre Ernst, MD, MSc (2) · Alison C Bested, MD FRCPC (1) · Amandine Zellag (1) · Anne Munck, Dr (1) · Ashley G Henderson, MD (1)
PMID 29187413, PMID 30658914, PMID 32554534, PMID 33595792, PMID 38954871, PMID 10453772, PMID 11744914, PMID 11790668, PMID 12668799, PMID 16840399, PMID 19183804, PMID 19996339, PMID 20405117, PMID 21893650, PMID 22561055, PMID 23258788, PMID 24862342, PMID 25972024, PMID 26288390, PMID 26325189, PMID 26935334, PMID 27007958, PMID 27479930, PMID 27748623, PMID 28205038, PMID 28232118, PMID 28495619, PMID 28586918, PMID 29371384, PMID 29487870, PMID 29578249, PMID 29890086, PMID 30073285, PMID 30216086, PMID 30230263, PMID 30805768, PMID 30962681, PMID 31428637, PMID 31451351, PMID 31467115, PMID 31505191, PMID 31844133, PMID 31847717, PMID 31999499, PMID 32050447, PMID 32373171, PMID 32423275, PMID 33709856, PMID 33887244, PMID 34144923
2014 (2), 2004 (1), 2018 (1), 2025 (1), K23MH096651 (1), M01RR000037 (1), N01AO50042 (1), P01HL108808 (1), R01DK057755 (1), R44HL107000 (1), U01HL080310 (1), U01HL114589 (1), U01HL114623 (1)